Company news

Share this article:
Altor BioScience Corporation entered into an agreement with Genentech for exclusive, worldwide rights to develop and commercialize a class of antibody-based tissue factor antagonists. Altor plans on initiating a multi-center, Phase II clinical study later this year, using the lead therapeutic antibody known as ALT-836 for the treatment of acute respiratory distress syndrome and acute lung injury. Financial terms of the licensing transaction were not disclosed.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.